The Unexpected Skin Effects of GLP-1 Drugs: A Systematic Review

GLP-1 receptor agonists show direct dermatological effects including potential benefits for inflammatory skin diseases, expanding their therapeutic profile beyond metabolism.

Persson, Calista et al.·Diseases (Basel·2025·Moderate EvidenceSystematic Review
RPEP-13029Systematic ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Systematic Review
Evidence
Moderate Evidence
Sample
N=Not applicable (review of 51 studies)
Participants
Patients on GLP-1 RAs with dermatological effects

What This Study Found

GLP-1 RAs exert direct dermatological effects including potential benefits in inflammatory skin diseases, expanding their known therapeutic profile beyond metabolic applications.

Key Numbers

51 studies met criteria. 34 reported adverse effects (hypersensitivity, injection-site reactions, pruritus, urticaria, angioedema, bullous pemphigoid). 17 reported beneficial outcomes (psoriasis, HS, wound healing).

How They Did This

Systematic review of EMBASE, PubMed, Web of Science, and Google Scholar from 2014-2025, including peer-reviewed human studies on GLP-1 RA dermatological effects.

Why This Research Matters

With millions of people now taking GLP-1 drugs, understanding skin effects helps clinicians and patients anticipate dermatological changes and could open new treatment paths for skin diseases.

The Bigger Picture

GLP-1 receptors throughout the body continue to reveal new therapeutic possibilities. Dermatological effects add yet another dimension to these increasingly versatile medications.

What This Study Doesn't Tell Us

Heterogeneous studies with varying designs. Some skin effects may be related to weight loss rather than direct GLP-1 receptor activity in skin.

Questions This Raises

  • ?Which inflammatory skin diseases respond best to GLP-1 RA treatment?
  • ?Are skin effects dose-dependent or specific to certain GLP-1 drugs?

Trust & Context

Key Stat:
2014-2025 evidence reviewed Decade of literature shows GLP-1 drugs have direct effects on skin beyond their metabolic benefits
Evidence Grade:
Systematic review of mostly observational studies and case reports. While methodologically sound, the underlying evidence is heterogeneous.
Study Age:
Published in 2025, providing the most comprehensive review of GLP-1 RA dermatological effects to date.
Original Title:
A Closer Look at the Dermatological Profile of GLP-1 Agonists.
Published In:
Diseases (Basel, Switzerland), 13(5) (2025)
Database ID:
RPEP-13029

Evidence Hierarchy

Meta-Analysis / Systematic ReviewCombines many studies into one answer
This study
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Analyzes all available research on a topic using a structured method.

What do these levels mean? →

Frequently Asked Questions

Can GLP-1 drugs affect your skin?

Yes. This review found both beneficial effects (particularly for inflammatory skin conditions) and some adverse skin reactions. GLP-1 receptors are present in skin cells, meaning these drugs can directly influence skin biology.

Could GLP-1 drugs help treat skin diseases like psoriasis?

Emerging evidence suggests possible benefits for inflammatory skin diseases. Some studies report improvements in psoriasis and other conditions. However, more research is needed before GLP-1 drugs could be recommended specifically for skin diseases.

Read More on RethinkPeptides

Cite This Study

RPEP-13029·https://rethinkpeptides.com/research/RPEP-13029

APA

Persson, Calista; Eaton, Allison; Mayrovitz, Harvey N. (2025). A Closer Look at the Dermatological Profile of GLP-1 Agonists.. Diseases (Basel, Switzerland), 13(5). https://doi.org/10.3390/diseases13050127

MLA

Persson, Calista, et al. "A Closer Look at the Dermatological Profile of GLP-1 Agonists.." Diseases (Basel, 2025. https://doi.org/10.3390/diseases13050127

RethinkPeptides

RethinkPeptides Research Database. "A Closer Look at the Dermatological Profile of GLP-1 Agonist..." RPEP-13029. Retrieved from https://rethinkpeptides.com/research/persson-2025-a-closer-look-at

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.